Pefloxacin Mesylate Capsules

This product has a broad-spectrum antibacterial effect and has good antibacterial effect on the following bacteria: most bacteria of the Enterobacteriaceae family, including Escherichia coli, Klebsiella, Proteus, Shigella, Typhi and Salmonella, as well as Haemophilus influenzae, Neisseria, etc. It also has a certain antibacterial effect on Pseudomonas aeruginosa and Staphylococcus aureus, but only has a slight effect on Pneumococcus, various groups of Streptococci and Enterococci. In addition, it also has antibacterial activity against Mycobacterium leprae. Pefloxacin mesylate is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibits DNA synthesis and replication, and causes bacterial death.

Pefloxacin mesylate

This product is a capsule, and the contents are white to slightly yellow powder.

Various infections caused by pefloxacin-sensitive bacteria: urinary tract infections; respiratory tract infections; ear, nose and throat infections; gynecological and reproductive system infections; abdominal and liver and gallbladder system infections; bone and joint infections; skin infections; sepsis and endocarditis; meningitis.

Oral administration: 0.2-0.4 g per day for adults, twice a day

Gastrointestinal reactions are common and may manifest as abdominal discomfort or pain, diarrhea, nausea or vomiting. Central nervous system reactions may include dizziness, headache, drowsiness or insomnia. Allergic reactions: rash, itchy skin, occasionally exudative erythema multiforme and angioedema, and a few patients may have photosensitivity reactions. Occasionally, the following may occur: (1) epileptic seizures, mental abnormalities, irritability, confusion, hallucinations, tremors, (2) interstitial nephritis symptoms such as hematuria, fever, and rash, (3) crystalluria, which is more common when high doses are used, and (4) joint pain. A small number of patients may experience elevated serum aminotransferase, increased blood urea nitrogen, and decreased peripheral white blood cells, which are mostly mild and transient.

Patients who are allergic to this product and fluoroquinolones are contraindicated.

Precautions for children: The safety of this product in infants and adolescents under 18 years of age has not been determined. However, this product can cause joint lesions when used in several young animals. Therefore, it should not be used in children and adolescents under 18 years of age. Precautions for pregnancy and lactation: Animal experiments have not confirmed that quinolones are teratogenic, but studies on the use of drugs in pregnant women have not yet reached a clear conclusion. Since this drug can cause joint lesions in underage animals, it is contraindicated for pregnant women, and lactating women should suspend breastfeeding when using this product. Precautions for the elderly: Elderly patients often have impaired renal function, and since this product is partially excreted through the kidneys, it needs to be used in reduced doses.

Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. When this product is used in combination with theophylline, competitive inhibition of the binding site of cytochrome P450 may lead to a significant reduction in the elimination of theophylline in the liver, a prolonged elimination half-life (t1/2β), an increase in blood concentration, and the occurrence of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, agitation, convulsions, palpitations, etc., and should be avoided. If it cannot be avoided, theophylline blood concentration should be measured and the dose adjusted. When cyclosporine is used in combination with this product, its blood concentration increases, and the blood concentration of cyclosporine must be monitored and the dose adjusted. When this product is used in combination with the anticoagulant warfarin, it can enhance the latter's anticoagulant effect. When used in combination, the patient's prothrombin time should be closely monitored and the dose adjusted. Probenecid can reduce the secretion of this product from the renal tubules by about 50%. When used in combination, it may cause toxicity due to the increased blood concentration of this product. This product interferes with the metabolism of caffeine, resulting in reduced caffeine elimination, prolonged blood elimination half-life (t1/2β), and possible central nervous system toxicity. When used together, the patient's blood caffeine concentration should be closely monitored and the dosage adjusted. Antacids containing aluminum and magnesium can reduce the oral absorption of this product and should not be used together.

Keep in a sealed container

0.1g (calculated as C17H20FN3O3)

24 months

Qingdao Guoda Pharmaceutical Co., Ltd.

• Founded in:

  2002-04-17

• Address:

  No. 750, Jinggangshan Road, Qingdao Economic and Technological Development Zone

• Tax NO.:

  913702117372658985

• Registered Funds:

  26.25 million yuan

• Website:

  Log in to view

• Email:

  Log in to view